经皮临时循环支持装置作为晚期心衰急性失代偿患者决策桥接的应用
这项多中心回顾性研究纳入58例晚期心衰急性失代偿且依赖正性肌力药物的患者,使用Impella 5.0进行决策桥接(BTD)。平均支持7天,67%存活至后续治疗(多数接受持久机械循环支持或心脏移植)。研究者认为Impella 5.0可提供BTD策略,但需前瞻性研究评估安全性和有效性。
要点
- Impella 5.0可作为晚期心衰急性失代偿患者的决策桥接策略。
- 58例患者中67%存活至后续治疗,其中持久MCS 20例、心脏移植15例。
- 院内并发症包括出血9例和溶血4例。
核心结论
- Impella 5.0可能为晚期心衰合并急性血流动力学不稳定的患者提供决策桥接策略。
- 需前瞻性研究评估该装置在此类患者中的安全性和有效性。
研究设计与样本
- 多中心(3中心)回顾性研究,纳入2010至2015年58例晚期心衰急性失代偿并接受Impella 5.0进行决策桥接的患者。
主要发现
- 58例患者均依赖正性肌力药物,平均射血分数13%,中位年龄59岁(四分位距48-64岁)。
- 平均支持时间7天(范围0-22天)。
- 院内并发症包括出血9例和溶血4例。
- 存活至后续治疗的患者中,1年生存率:持久MCS组65%,移植组87%,稳定后撤机组75%。
临床怎么用
- 对于晚期心衰急性失代偿且依赖正性肌力药物的患者,可考虑使用Impella 5.0进行短期血流动力学稳定,以便评估后续治疗(持久MCS、心脏移植或姑息治疗)。
局限性
- 回顾性研究设计。
- 样本量较小(58例)。
- 需前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prognosis is poor for patients with decompensated advanced heart failure (HF) refractory to medical therapy. Evaluating candidacy for durable mechanical circulatory support (MCS), cardiac transplantation, or palliative care is complex, and time is often needed to stabilize the patient hemodynamically. The Impella 5.0 (Abiomed, Danvers, MA) is a minimally invasive axial-flow catheter capable of providing full temporary hemodynamic support. We report a multicenter series on the use of this device for bridge to decision (BTD) in decompensated advanced HF patients. METHODS: In a retrospective evaluation at 3 centers of patients with advanced HF who acutely decompensated and received the Impella 5.0 for BTD, we analyzed demographics, procedural characteristics, in-hospital and intermediate-term outcomes, and in-hospital complications. RESULTS: There were 58 patients who met inclusion criteria from 2010 to 2015. All were inotrope dependent. The mean ejection fraction was 13%, and median age was 59 years (interquartile range, 48-64 years). Mean duration of support was 7 days (range, 0-22 days). Thirty-nine patients survived to next therapy (67%), with most receiving durable MCS (n = 20) or heart transplantation (n = 15). In-hospital complications included bleeding (n = 9) and hemolysis (n = 4). Of patients who survived to the next therapy, 1-year survival was 65% for those who received durable MCS, 87% for those who received a transplant, and 75% for those who were stabilized and weaned. CONCLUSIONS: The Impella 5.0 may provide a BTD strategy for patients with advanced HF and acute hemodynamic instability. Prospective studies are needed to evaluate the safety and effectiveness of this device in this patient population.
引用
- Hall SA, Uriel N, Carey SA, et al. Use of a percutaneous temporary circulatory support device as a bridge to decision during acute decompensation of advanced heart failure. J Heart Lung Transplant. 2017. PMID: 29056460. doi:10.1016/j.healun.2017.09.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。